Low-Flow, Low-Gradient Aortic Stenosis
Conditions
Keywords
Aortic Stenosis, Low-Flow, Low-Gradient, TAVI
Brief summary
The ATLAS TAVI Registry is a retrospective, investigator-initiated, multicenter registry including patients, who underwent Transcatheter Aortic Valve Implantation (TAVI) for classical or paradoxical low-flow, low-gradient aortic stenosis (LFLG AS) with available non-contrast MSCT data on aortic valve calcification (AVC). The main objective of this study is the assessment of outcome after TAVI according to AVC density severity in patients with LFLG AS.
Detailed description
Aortic valve calcification (AVC) as assessed by MSCT is highly correlated with aortic stenosis (AS) severity and, thus, has become an important tool for diagnosing severe AS, especially in patients with low-flow low-gradient aortic stenosis (LFLG AS). Moreover, in medically treated AS patients AVC is directly associated with poor prognosis. In contrast, the prognostic benefit of eliminating AS by Transcatheter Aortic Valve Implantation (TAVI) in patients with LFLG AS seems to be larger in patients with high AVC density (AVCd) compared to those with low AVCd, at least in classical (low EF) LFLG AS. Hence, we hypothesize that AVCd might be a valuable marker for treatment response among TAVI patients with LFLG AS, who are known to suffer from poor outcome even after elimination of AS. The multicentric ATLAS TAVI Registry of LFLG AS patients, who underwent TAVI, assesses the impact of AVCd on outcome in these patients.
Interventions
None listed
Sponsors
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Universitätsklinikum Hamburg-Eppendorf
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* age ≥18 years * patient gave written informed consent for data acquisition and transfer * for LFLG AS: -- available non-contrast MSCT data on aortic valve calcification (AVC, Agatston Units)
Exclusion criteria
\- LFLG AS without non-contrast MSCT data on AVC
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| All-cause mortality | 12 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cardiovascular Mortality | 12 months | Incidence of cardiovascular death, defined as death attributable to myocardial ischemia and infarction, heart failure, cardiac arrest because of other or unknown cause, or cerebrovascular accident. |
| Rehospitalizations for congestive heart failure | 12 months | Incidence of new-onset or worsening signs and symptoms of heart failure that required urgent therapy and resulted in hospitalization, e.g. as assessed by patient interviews or hospital records. |
Countries
Canada, Denmark, France, Germany, Israel, Netherlands, United Kingdom
Contacts
Primary ContactNiklas Schofer, MD
Backup ContactSebastian Ludwig, MD
Outcome results
None listed